Amgen is posting strong growth across its diversified-medicines portfolio. A new weight-loss drug candidate could be a game-changer for the company. Trading at 17 times earnings, the stock offers ...

(RTTNews) - Amgen Inc. (AMGN) Tuesday announced positive ... These results will be presented at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session during the American ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. At the same time ...

Salveen Richter has given his Buy rating due to a combination of factors that highlight Amgen’s potential growth prospects. A critical focus is on the upcoming Phase 2 obesity data for MariTide ...

Oct. 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN ... parallel-group trial will be presented at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session during the American Association ...